Table of Contents Table of Contents
Previous Page  685 / 812 Next Page
Information
Show Menu
Previous Page 685 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S681

similarly, opening a new line of research and treatment of condi-

tions with these characteristics.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2022

EV1038

The role of long-acting antipsychotic

treatment in schizophrenia with

comorbid drug use. The case of

paliperidone palmitate

A. Portilla Fernández

1

, L. Reula

2

, E. Manrique Astiz

3

,

L.A. Nú˜nez Domínguez

4 ,

, O. Arbeo Ruiz

5

, M. García Nicolás

6

,

O. Fernández de la Vega

7

1

Clíncia de Rehabilitación, Psychiatry, Pamplona/Iru˜na, Spain

2

Hospital de Día, Psychiatry, Pamplona/Iru˜na, Spain

3

Mental Health Center, Psychiatry, Tafalla, Spain

4

Centro Médico, Psychiatry, Pamplona, Spain

5

Centro de Día Zuría, Psychiatry, Pamplona/Iru˜na, Spain

6

Mental Health Center, Psychiatry, Tudela, Spain

7

Mental Health Center, Psychiatry, Pamplona/Iru˜na, Spain

Corresponding author.

The patient suffering a schizophrenic disorder with a comorbid

drug use is a challenge for the technical team of psychiatrists who

provide to control this disorder. In some guides that include a

revision of the efficacy of several psychopharmacological and/or

psychological treatment shows that there any treatment has no

efficacy in this group of patients. But it suggests that long-acting

antipsychotic may play a role in some cases with no adherence.

We study prospectively some data in a group of patients of these

characteristics treated with paliperidone palmitate as main psy-

chopharmacological treatment, using asmeasurements of outcome

the number of psychiatric admissions, dosage of oral treatment, use

of drug before and after the beginning of Paliperdione Palmitate.

Our results show that it exists a decrease of number of admissions,

dosage of oral concomitant treatment and drug use, with a very

good adherence and no dropouts in the follow-up. We conclude

that Paliperidone Palmitate may be a very good alternative for the

psychopharmacological treatment in schizophrenic patients with

comorbid drug use.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2023

EV1039

Heavy cannabis use impairs verbal

memory of first psychotic episode

patients

C. Nu˜nez

1

, S. Ochoa

1

, E. Huerta-Ramos

2

, I. Ba˜nos

1

, A. Barajas

3

,

M. Dolz

4

, B. Sanchez

5

, N. Del Cacho

6

, G. Genipe

7

, J. Usall

6 ,

1

Parc Sanitari Sant Joan de Déu, CIBERSAM, Research Unit, Sant Boi

de Llobregat, Spain

2

Parc Sanitari Sant Joan de Deu, CIBERSAM, Research Unit, Sant Boi

de Llobregat, Spain

3

Centre d’ Higiene Mental Les Corts, Research Unit, Barcelona, Spain

4

Hospital Materno Infantil Sant Joan de Déu- Esplugues, Psychiatry

Department, Esplugues de Llobregat, Spain

5

Hospital Materno Infantil Sant Joan de Déu, Psychiatry Department,

Esplugues de Llobregat, Spain

6

Parc Sanitari Sant Joan de Déu, Research Unit, Sant Boi de Llobregat,

Spain

7

Parc Sanitari Sant Joan de Déu, Psychiatry Research, Sant Boi de

Llobregat, Spain

Corresponding author.

Introduction

Cannabis consumption is known to be increased

in both schizophrenic and first psychotic episode patients. Con-

trary to what has been reported in studies with healthy people,

all published studies so far have reported no impairments or even

beneficial effects on neurocognition associated with cannabis con-

sumption in schizophrenia and first psychotic episode patients.

However, these studies did not address the effects of very high

cannabis consumption.

Objective

Our aim in this study was to assess the effects on neu-

rocognition of regular and heavy cannabis consumption in first

psychotic episode patients.

Methods

A total of 74 patients were included in the study and

assigned to 3 different groups according to their mean cannabis

consumption during the last year (non-users, regular users, and

heavy users). Participants were administered verbal memory,

attention, processing speed, working memory, vocabulary, arith-

metic and spatial orientation tasks.

Results

Our results showed the heavy cannabis group of first psy-

chotic episode patients to be significantly impaired in all the verbal

memorymeasures with respect to the non-users group. There were

no significant differences between regular users and non-users.

Moreover, regular cannabis consumption was associated with an

improvement in some attention and processing speed measures.

Conclusions

Our data showed heavy cannabis consumption to

impair verbal memory in first psychotic episode patients and sug-

gest a dose-related effect of cannabis consumption, since regular

consumption did not impair verbal memory and may be beneficial

for other tasks.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2024

EV1040

Choosing an antipsychotic on a case of

late-onset psychosis – A challenge on

everyday practice

M. Oliveira

, M.

J. Peixoto , C. Novais , C. Santos

Centro Hospitalar São João, EPE, Psychiatry and Mental Health Clinic,

Porto, Portugal

Corresponding author.

Introduction

Psychosis with onset in late adulthood already con-

stitutes a challenge on the differential diagnosis and treatment,

especially in polypharmacy patients.

Methods and aims

We present a case report of a 61-year old

woman with a late-onset psychosis and discuss the clinical evo-

lution and the pharmacological treatment.

Results

The patient suffered from obesity, type II diabetes melli-

tus with poor glycemic control, and hypertension. She had a first

psychotic episode at the age of 56, having persecutory delusional

ideas and auditory hallucinations with psychomotor agitation and

insomnia. She was first medicated with an atypical antipsychotic

(olanzapine) with little response and worsening of the glycemic

control. A switch was performed to haloperidol with remission of

symptomatology with low doses (4mg/day). Through follow-up

the doses of haloperidol was decreased and eventually suspended,

but having a relapse a few months later. Haloperidol was again

introduced and the symptoms remitted. Stability was maintained,

but the patient started to show lower limbs symmetrical rigidity

and psychomotor retardation. It was decided to switch haloperidol

to risperidone, but the patient reported side effects with its use,

and had to stop it. Haloperidol was again introduced, but had to be

discontinued after motor symptoms got worse. Again the patient

had another recurrence of psychotic symptoms and it was decided

to introduce paliperidone (6mg/day) with good response and tol-

erability.

Conclusions

The safety and tolerability of antipsychotic medi-

cation is variable. When choosing a treatment in a patient with